Submit Deal

RECURSION PHARMACEUTICALS

HQ - Salt Lake City

Summary

Recursion Pharmaceuticals is a clinical-stage biotechnology company focused on decoding biology to accelerate drug discovery using advanced technologies like artificial intelligence, automation, and high-throughput experimentation.

Deals Overview

Total Deals5

Valued Deals2

Total Value£ 609 M

Avg. Deal Size£ 305 M

Market Context

Senior Management

Chris Gibson
Co-Founder and CEO
Michael Secora
CFO
Nathan Hatfield
Chief Legal Officer

Sort

03 Oct 2017|United States|Pharmaceuticals

Target: RECURSION PHARMACEUTICALS

Bidder: MUBADALA INVESTMENT COMPANY

1 Service Providers

1 Bidder

2 Dealmakers

2 Bidder

n/a

Value

28 Jul 2020|United States|Biotechnology

Target: VIUM INC

Bidder: RECURSION PHARMACEUTICALS

2 Service Providers

1 Target | 1 Bidder

3 Dealmakers

1 Target | 2 Bidder

n/a

Value

08 May 2023|Canada|Software

Target: CYCLICA

Bidder: RECURSION PHARMACEUTICALS

4 Service Providers

3 Target | 1 Bidder

11 Dealmakers

10 Target | 1 Bidder

£ 69 M

Value

08 Aug 2024|United Kingdom|Biotechnology

Target: EXSCIENTIA

Bidder: RECURSION PHARMACEUTICALS

8 Service Providers

3 Target | 5 Bidder

62 Dealmakers

7 Target | 55 Bidder

£ 539 M

Value

28 Feb 2025|Austria|Biotechnology

Target: ALPHA BIOTECHNOLOGY GMBH

Bidder: INSTITUTIONAL INVESTORS

2 Service Providers

2 Vendor

2 Dealmakers

2 Vendor

n/a

Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy